Morgan Stanley is out with its report today on CVS/Caremark CVS, maintaining Equal-weight.
In its report, Morgan Stanley writes, 'Valuation is temping, but after years of disappointments, CVS needs to prove its PBM operating income performance to the market. We maintain our Equal-weight rating."
Shares of CVS closed Tuesday at $33.80.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
